BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73. Please ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion. CureVac’s research and manufacturing site in Tübingen, Germany, will be integrated into the larger biotech company. By .

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution ...

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business.

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with Bristol-Myers and its impact on the firm.

Summary. BioNTech SE acquires CureVac N.V. in an all-stock-deal, valuing the company at $1.25 billion. The acquisition brings complementary technologies as both are developing mRNA candidates for ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.18, with a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 3.58% ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...